Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 17

    1.

    Natural history and outcome of mucinous carcinoma of the ovary.

    Schiavone MB, Herzog TJ, Lewin SN, Deutsch I, Sun X, Burke WM, Wright JD.

    Am J Obstet Gynecol. 2011 Nov;205(5):480.e1-8. Epub 2011 Jun 21.

    PMID:
    21861962
    [PubMed - indexed for MEDLINE]
    2.

    Clinical characteristics of ovarian teratoma: age-focused retrospective analysis of 580 cases.

    Kim MJ, Kim NY, Lee DY, Yoon BK, Choi D.

    Am J Obstet Gynecol. 2011 Jul;205(1):32.e1-4. Epub 2011 Feb 23.

    PMID:
    21507373
    [PubMed - indexed for MEDLINE]
    3.

    CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial.

    Alexandre J, Brown C, Coeffic D, Raban N, Pfisterer J, Mäenpää J, Chalchal H, Fitzharris B, Volgger B, Vergote I, Pisano C, Ferrero A, Pujade-Lauraine E.

    Br J Cancer. 2012 Feb 14;106(4):633-7. doi: 10.1038/bjc.2011.593. Epub 2012 Jan 12.

    PMID:
    22240800
    [PubMed - indexed for MEDLINE]
    4.

    Epigenetic biomarkers in epithelial ovarian cancer.

    Gloss BS, Samimi G.

    Cancer Lett. 2012 Jan 12. [Epub ahead of print]

    PMID:
    22245949
    [PubMed - as supplied by publisher]
    5.

    Expression of the tumor suppressor miR-206 is associated with cellular proliferative inhibition and impairs invasion in ERα-positive endometrioid adenocarcinoma.

    Chen X, Yan Q, Li S, Zhou L, Yang H, Yang Y, Liu X, Wan X.

    Cancer Lett. 2012 Jan 1;314(1):41-53. Epub 2011 Sep 21.

    PMID:
    21983130
    [PubMed - indexed for MEDLINE]
    6.

    High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.

    Yoshihara K, Tsunoda T, Shigemizu D, Fujiwara H, Hatae M, Fujiwara H, Masuzaki H, Katabuchi H, Kawakami Y, Okamoto A, Nogawa T, Matsumura N, Udagawa Y, Saito T, Itamochi H, Takano M, Miyagi E, Sudo T, Ushijima K, Iwase H, Seki H, Terao Y, Enomoto T, Mikami M, Akazawa K, Tsuda H, Moriya T, Tajima A, Inoue I, Tanaka K; Japanese Serous Ovarian Cancer Study Group.

    Clin Cancer Res. 2012 Mar 1;18(5):1374-85. Epub 2012 Jan 12.

    PMID:
    22241791
    [PubMed - in process]
    7.

    Minocycline inhibits growth of epithelial ovarian cancer.

    Pourgholami MH, Mekkawy AH, Badar S, Morris DL.

    Gynecol Oncol. 2012 May;125(2):433-40. Epub 2012 Jan 16.

    PMID:
    22252097
    [PubMed - in process]
    8.

    A clinicopathologic study of gynecologic organ involvement at radical cystectomy for bladder cancer.

    Salem H, El-Mazny A.

    Int J Gynaecol Obstet. 2011 Nov;115(2):188-90. Epub 2011 Aug 26.

    PMID:
    21872241
    [PubMed - indexed for MEDLINE]
    9.

    Management of ovarian carcinoid syndrome.

    Pappa I, Peros G, Lappas C, Vassiliu P, Arkadopoulos N, Smyrniotis V.

    Int J Gynaecol Obstet. 2011 Nov;115(2):205-7. Epub 2011 Aug 26. No abstract available.

    PMID:
    21872235
    [PubMed - indexed for MEDLINE]
    10.

    Finding ovarian cancer.

    Hartge P, Speyer JL.

    J Natl Cancer Inst. 2012 Jan 18;104(2):82-3. Epub 2012 Jan 13. No abstract available.

    PMID:
    22247023
    [PubMed - indexed for MEDLINE]
    11.

    Predictive value of symptoms for ovarian cancer: comparison of symptoms reported by questionnaire, interview, and general practitioner notes.

    Lim AW, Mesher D, Gentry-Maharaj A, Balogun N, Jacobs I, Menon U, Sasieni P.

    J Natl Cancer Inst. 2012 Jan 18;104(2):114-24. Epub 2012 Jan 13.

    PMID:
    22247022
    [PubMed - indexed for MEDLINE]
    12.

    Early detection of ovarian cancer in symptomatic women.

    van Nagell JR Jr.

    Lancet Oncol. 2012 Mar;13(3):223-4. Epub 2012 Jan 17. No abstract available.

    PMID:
    22257525
    [PubMed - indexed for MEDLINE]
    13.

    Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project.

    Gilbert L, Basso O, Sampalis J, Karp I, Martins C, Feng J, Piedimonte S, Quintal L, Ramanakumar AV, Takefman J, Grigorie MS, Artho G, Krishnamurthy S; DOvE Study Group.

    Lancet Oncol. 2012 Mar;13(3):285-91. Epub 2012 Jan 17.

    PMID:
    22257524
    [PubMed - indexed for MEDLINE]
    14.

    The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion.

    Jeong KJ, Park SY, Cho KH, Sohn JS, Lee J, Kim YK, Kang J, Park CG, Han JW, Lee HY.

    Oncogene. 2012 Jan 16. doi: 10.1038/onc.2011.595. [Epub ahead of print]

    PMID:
    22249252
    [PubMed - as supplied by publisher]
    15.

    Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.

    Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS, Rizzo S, van der Zee A, Plumb JA, Brown R.

    Oncogene. 2012 Jan 16. doi: 10.1038/onc.2011.611. [Epub ahead of print]

    PMID:
    22249249
    [PubMed - as supplied by publisher]
    16.

    Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer.

    Peng DX, Luo M, Qiu LW, He YL, Wang XF.

    Oncol Rep. 2012 Apr;27(4):1238-44. doi: 10.3892/or.2012.1625. Epub 2012 Jan 11.

    PMID:
    22246341
    [PubMed - indexed for MEDLINE]
    17.

    A risk-adapted strategy of adjuvant paclitaxel/carboplatin in early-stage ovarian cancer: time-dependent effect of 4 versus 6 cycles on outcome.

    Bamias A, Bamia C, Karadimou A, Soupos N, Zagouri F, Rodolakis A, Haidopoulos D, Vlahos G, Thomakos N, Antsaklis A, Dimopoulos MA.

    Oncology. 2011;81(5-6):365-71. Epub 2012 Jan 13.

    PMID:
    22248920
    [PubMed - in process]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk